文献速递消化道肿瘤放疗胸部肿瘤放疗

基于肺癌的两年死亡率预测模型在食管癌患者队列中的外部验证

External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts.
PubMed 文献 · Radiother Oncol · 2023-11-09

该研究在来自3个荷兰中心的5个食管癌患者队列中,对先前基于肺癌患者开发的、使用平均心脏剂量(MHD)和肿瘤大体体积(GTV)预测2年总死亡率的模型进行外部验证。在根治性放化疗(n=170)和新生辅助放化疗(n=568)患者中分别评估外部效度,根据校准和区分度结果对模型进行更新。更新后模型在两组中均显示良好校准,c统计量分别为0.67(95%CI:0.58-0.75)和0.62(95%CI:0.57-0.67)。

要点

  • 在根治性放化疗食管癌患者中,调整截距后模型校准良好,c统计量为0.67(95%CI:0.58-0.75)。
  • 在新生辅助放化疗食管癌患者中,需同时调整斜率和截距,重校准后c统计量为0.62(95%CI:0.57-0.67)。
  • 基于MHD和GTV的肺癌2年死亡率预测模型在食管癌患者中更新截距和/或斜率后表现良好。

核心结论

  • 基于MHD和GTV的肺癌患者2年死亡率预测模型,在更新原模型的截距和/或斜率后,在食管癌患者中表现出良好性能。

研究设计与样本

  • 使用来自3个荷兰中心的5个食管癌患者队列进行外部验证,分别在根治性放化疗(n=170)和新生辅助放化疗(n=568)患者中评估模型外部效度。
  • 通过校准图、校准-in-the-large(CITL)和校准斜率(CS)评估校准,通过c统计量评估区分度;若模型性能欠佳则对模型进行更新。

主要发现

  • 根治性放化疗患者中,调整截距后校准良好(CITL 0.00;CS 1.08),调整后模型c统计量为0.67(95%CI:0.58-0.75)。
  • 新生辅助放化疗患者中,因验证人群初始校准不良需同时调整斜率和截距(CITL 0.00;CS 1.72),重校准后模型校准完美(即CITL 0,CS 1),重校准模型c统计量为0.62(95%CI:0.57-0.67)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/OBJECTIVE: Chemo-radiotherapy can improve the oncological outcome of esophageal cancer (EC) patients, but may cause long term radiation-induced toxicity, including an increased risk of non-cancer related death. For lung cancer patients, a model to predict 2-year total mortality using mean heart dose (MHD) and gross tumor volume (GTV) has previously been developed and validated. This project aimed to externally validate this model in EC patients. METHODS: Five EC patient cohorts from 3 different Dutch centres were used for model validation. External validity of the model was assessed separately in definitive (n = 170) and neo-adjuvant (n = 568) chemoradiotherapy (dCRT and nCRT) patients. External validity was assessed in terms of calibration by calibration plots, calibration-in-the-large (CITL) and calibration slope (CS), and discrimination by assessment of the c-statistic. If suboptimal model performance was observed, the model was further updated accordingly. RESULTS: For the dCRT patients, good calibration was found after adjustment of the intercept (CITL 0.00; CS 1.08). The c-statistic of the adjusted model was 0.67 (95%CI: 0.58 to 0.75). For nCRT patients the model needed adjustment of both the slope and the intercept because of initial miscalibration in the validation population (CITL 0.00; CS 1.72). After recalibration, the model showed perfect calibration (i.e., CITL 0, CS 1), as is common after recalibration. The c-statistic of the recalibrated model equaled 0.62 (95%CI: 0.57 to 0.67). CONCLUSION: The existing model for 2-year mortality prediction in lung cancer patients, based on the predictive factors MHD and GTV, showed good performance in EC patients after updating the intercept and/or slope of the original model.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Berbée M, Muijs CT, Voncken FEM, et al. External validation of a lung cancer-based prediction model for two-year mortality in esophageal cancer patient cohorts. Radiother Oncol. 2023. PMID: 37949374. doi:10.1016/j.radonc.2023.109979

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。